Yurogen Biosystems is an international biotech company dedicated to monoclonal antibody development. We were established in Boston, Massachusetts in 2014. In 2018, Yurogen set up a Chinese branch in Wuhan China to expand CRO services in East Asia. In 2021, we merged with ABclonal Science Inc, a growing provider of biological reagents and services in the global market.

Our state-of-the-art SMab™ platform, a single-B-cell-based monoclonal antibody development technology, has enabled us to successfully develop a variety of antibodies, including rabbit, llama, and human monoclonal antibodies, providing antibody-based solutions for scientific research, in vitro diagnostics, and antibody-related drug development applications.

Through innovative research and development, Yurogen Biosystems has become a preeminent leader in the field of customized antibody discovery, engineering, and production, serving various leading biotechnology and pharmaceutical companies in the U.S. and abroad.